(London) – Anglo-Swedish pharmaceutical AstraZeneca admitted on Tuesday that a study of its treatment with monoclonal antibodies -AZD7442- did not meet the main objective of preventing symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.
In a statement, the Anglo-Swedish company indicated that the participants in this trial were over 18 years of age who had not been vaccinated and who had been exposed to a person with coronavirus in a period of eight days.
What is the effectiveness of the AstraZeneca vaccine
AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% compared to a placebo, which was not statistically significant, according to the company.
The expert in Pediatrics from the University of Colorado School of Medicine Myron Levin highlighted in the note the importance of having treatments for people who cannot be vaccinated against COVID-19.
Monoclonal antibody treatment belongs to a group of drugs that simulate the natural antibodies that the body produces to fight infection.
